Replacement therapy for breast cancer survivors. A pilot study.
作者信息
DiSaia P J, Grosen E A, Odicino F, Cowan B, Pecorelli S, Wile A G, Creasman W T
机构信息
Department of Obstetrics and Gynecology, University of California at Irvine, College of Medicine, Orange 92668, USA.
出版信息
Cancer. 1995 Nov 15;76(10 Suppl):2075-8. doi: 10.1002/1097-0142(19951115)76:10+<2075::aid-cncr2820761328>3.0.co;2-2.
BACKGROUND
Traditionally, breast cancer survivors were not considered as candidates for hormone replacement therapy (HRT) because of the possibility that an occult metastatic site of disease might be activated, thus negatively influencing the outcome for the patient.
METHODS
A retrospective review of 77 breast cancer survivors who have taken HRT was conducted.
RESULTS
Seven recurrences were reported among the 77 patients studied in-depth, with correlations to stage, age, and node and receptor status. There have been no recurrences among the 33 additional patients who were placed on the study after the completion of this analysis.
CONCLUSIONS
No significant adverse outcome was detected in this group of breast cancer survivors receiving HRT. Given the established benefits of HRT, a reappraisal of this subject is necessary, and a prospective randomized trial is essential.
Zotero 插件